ORIC: Advancing late-stage cancer programs with strong safety differentiation and robust financial runway

The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, now in Phase III, and enozertinib for lung cancer, with a key data update expected soon. Differentiation is driven by safety and brain penetrance, with large commercial opportunities and a strong cash runw…